GlassScriptPhysician profile
Kyla K Berreth
NPI 1225086093
$2,192.91
in general payments reported to CMS, 2019-2025
25 companies · $337 in 2025
The $337 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $239 · 2021: $537 · 2022: $357 · 2023: $264 · 2024: $229 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $374.78 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $305.93 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $178.88 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $166.81 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Sanofi Pasteur INC. | $142.91 | 2020-2025 | |
| Pfizer INC. | $139.51 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $135.77 | 2021-2022 | |
| Sobi, INC | $122.05 | 2020-2023 | |
| Corium, LLC | $107.07 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $84.65 | 2020-2022 | |
| Tris Pharma INC | $60.20 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $50.80 | 2021-2024 | Crysvita |
| Collegium Pharmaceutical, INC. | $49.93 | 2025 | Jornay Pm |
| Philips North America LLC | $40.69 | 2019 | |
| Baxter Healthcare | $31.35 | 2025 | Hillrom - Monarch Airway Clearance System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $28.76 | 2023 | Livmarli |
| Adlon Therapeutics L.P. | $26.45 | 2020 | |
| Kyowa Kirin, INC. | $25.11 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $22.53 | 2025 | Neffy |
| Organon LLC | $22.19 | 2025 | Jada System |
| Biogen, INC. | $16.99 | 2021 | |
| Noven Therapeutics, LLC | $16.97 | 2024 | Secuado, Xelstrym |
| Ossur Americas, INC. | $15.27 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.21 | 2025 | Koselugo |
| Seqirus USA INC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Berreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.